drugset / Trial / NCT06081894
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
RandomizedParallel-groupDouble-blindTreatment
Summary
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Timeline
- Start
- 2023-08-30
- Primary completion
- 2026-06
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aficamten | Small molecule | 5 mg | Oral |
| Subject | Aficamten | Small molecule | 10 mg | Oral |
| Subject | Aficamten | Small molecule | 15 mg | Oral |
| Subject | Aficamten | Small molecule | 20 mg | Oral |